Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy

Journal of Cardiovascular Magnetic Resonance

Volumn 15, Issue 1, 2013, Pages

  Pepe, Alessia ^a   Meloni, Antonella ^a   Rossi, Giuseppe ^a   Cuccia, Liana ^b   D'Ascola, Giuseppe Domenico ^c   Santodirocco, Michele ^d   Cianciulli, Paolo ^e   Caruso, Vincenzo ^f   Romeo, Maria Antonietta ^g   Filosa, Aldo ^h   Pitrolo, Lorella ⁱ   Putti, Maria Caterina ^j   Peluso, Angelo ^k   Campisi, Saveria ^l   Missere, Massimiliano ^m   Midiri, Massimo ⁿ   Gulino, Letizia ^a   Positano, Vincenzo ^a   Lombardi, Massimo ^a   Ricchi, Paolo ^h  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b Gastroenterology Unit   (Italy)

^c UO Microcitemie   (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^e S EUGENIO HOSPITAL   (Italy)

^f GARIBALDI HOSPITAL   (Italy)

^g UNIVERSITY OF CATANIA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ Az Osp Villa Sofia CTO   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

^k Presidio Ospedaliero Centrale   (Italy)

^l UOS Talassemia   (Italy)

^m CATHOLIC UNIVERSITY   (Italy)

ⁿ UNIVERSITY OF PALERMO   (Italy)

more..

Author keywords

Cardiovascular magnetic resonance; Chelation therapy; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART; HEART EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE; HUMAN; IMAGE RECONSTRUCTION; IRON BLOOD LEVEL; IRON OVERLOAD; LIVER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THALASSEMIA MAJOR; TREATMENT DURATION;

ADULT; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; CARDIOMYOPATHIES; CHI-SQUARE DISTRIBUTION; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON CHELATING AGENTS; ITALY; LIVER; MAGNETIC RESONANCE IMAGING, CINE; MALE; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PYRIDONES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; YOUNG ADULT;

EID: 84872193593     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-15-1     Document Type: Article

References (31)

1. Cardiac morbidity and mortality in Deferoxamine- or Deferiprone-treated patients with thalassemia major. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A, Blood 2006 107 3733 3737 10.1182/blood-2005-07-2933 16373663
2. Randomized controlled trial of Deferiprone or Deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, et al. Blood 2006 107 3738 3744 10.1182/blood-2005- 07-2948 16352815
3. Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. Pepe A, Lombardi M, Positano V, Cracolici E, Capra M, Malizia R, Prossomariti L, de Marchi D, Midiri M, Maggio A, Eur J Haematol 2006 76 183 192 10.1111/j.1600-0609.2005.00587.x 16451393
4. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with Deferoxamine and Deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ, Circulation 2007 115 1876 1884 10.1161/CIRCULATIONAHA. 106.648790 17372174 (Pubitemid 46598901)
5. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ, J Cardiovasc Magn Reson 2008 10 12 10.1186/1532-429X-10-12 18298856
6. A randomized controlled 1-year study of daily Deferiprone plus twice weekly desferrioxamine compared with daily Deferiprone Monotherapy in patients with thalassemia major. Aydinok Y, Ulger Z, Nart D, Terzi A, Cetiner N, Ellis G, Zimmermann A, Manz C, Haematologica 2007 92 1599 1606 10.3324/haematol.11414 18055982 (Pubitemid 350248238)
7. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V, J Cardiovasc Magn Reson 2009 11 20 10.1186/1532-429X-11-20 19558722
8. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 22 2171 2179 10.1053/euhj.2001.2822 11913479 (Pubitemid 33139463)
9. Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. Pepe A, Positano V, Santarelli F, Sorrentino F, Cracolici E, De Marchi D, Maggio A, Midiri M, Landini L, Lombardi M, J Magn Reson Imaging 2006 23 662 668 10.1002/jmri.20566 16568436
10. On T2* magnetic resonance and cardiac iron. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, et al. Circulation 2011 123 1519 1528 10.1161/CIRCULATIONAHA.110. 007641 21444881
11. Improved T2* assessment in liver iron overload by magnetic resonance imaging. Positano V, Salani B, Pepe A, Santarelli MF, De Marchi D, Ramazzotti A, Favilli B, Cracolici E, Midiri M, Cianciulli P, et al. Magn Reson Imaging 2009 27 188 197 10.1016/j.mri.2008.06.004 18667287
12. Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload. Meloni A, Luciani A, Positano V, De Marchi D, Valeri G, Restaino G, Cracolici E, Caruso V, Dellamico MC, Favilli B, et al. J Magn Reson Imaging 2011 33 348 355 10.1002/jmri.22417 21274976
13. Study of heart function. Sironi M, Lombardi M, Pepe A, De Marchi D, MRI of Heart and Vessels, Lombardi M, Bartolozzi C, S-VI 2005
14. Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. Ramazzotti A, Pepe A, Positano V, Rossi G, De Marchi D, Brizi MG, Luciani A, Midiri M, Sallustio G, Valeri G, et al. J Magn Reson Imaging 2009 30 62 68 10.1002/jmri.21781 19557847
15. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Meloni A, Ramazzotti A, Positano V, Salvatori C, Mangione M, Marcheschi P, Favilli B, De Marchi D, Prato S, Pepe A, et al. Int J Med Inform 2009 78 503 512 10.1016/j.ijmedinf.2009.02.011 19345609
16. Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts. Positano V, Pepe A, Santarelli MF, Scattini B, De Marchi D, Ramazzotti A, Forni G, Borgna-Pignatti C, Lai ME, Midiri M, et al. NMR Biomed 2007 20 578 590 10.1002/nbm.1121 17205488 (Pubitemid 47496898)
17. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the cardiac imaging committee of the council on clinical cardiology of the American heart association. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ, Rumberger JA, Ryan T, Verani MS, Circulation 2002 105 539 542 10.1161/hc0402.102975 11815441 (Pubitemid 34262671)
18. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ, J Magn Reson Imaging 2003 18 33 39 10.1002/jmri.10332 12815637 (Pubitemid 36791266)
19. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD, Blood 2005 106 1460 1465 10.1182/blood-2004-10-3982 15860670 (Pubitemid 41129616)
20. Hepatic iron concentration and total body iron stores in thalassemia major. Angelucci E, Brittenham GM, McLaren CE, Ripalti M, Baronciani D, Giardini C, Galimberti M, Polchi P, Lucarelli G, N Engl J Med. 2000 343 327 31 10.1056/NEJM200008033430503 10922422 (Pubitemid 30616698)
21. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. Marsella M, Borgna-Pignatti C, Meloni A, Caldarelli V, DellAmico MC, Spasiano A, Pitrolo L, Cracolici E, Valeri G, Positano V, et al. Haematologica 2011 96 515 520 10.3324/haematol.2010.025510 21228034
22. Left Ventricular volumes, mass and function normalized to the body surface area, age and gender from CMR in a large cohort of well-treated thalassemia major patients without myocardial iron overload. Meloni A, Aquaro GD, Festa P, Gagliardotto F, Zuccarelli A, Gearardi C, Santodirocco M, Romeo MA, Gamberini MR, Chiodi E, et al. Haematologica 2011 96 620 1577
23. Right ventricular volumes and function normalized to body surface area, age and sex in a large cohort of well-treated thalassemia major without myocardial iron overload. Meloni A, Aquaro GD, Ait-Ali L, Campisi S, Quarta A, Bisconte MG, Piraino B, Peluso A, Renne S, Positano V, et al. Haematologica 2011 96 620 1578
24. Reduction of body iron stores to normal range levels in thalassaemia by using a Deferiprone/Deferoxamine combination and their maintenance thereafter by Deferiprone Monotherapy. Kolnagou A, Kleanthous M, Kontoghiorghes GJ, Eur J Haematol 2010 85 430 438 10.1111/j.1600-0609.2010.01499.x 20662901
25. Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. Positano V, Pepe A, Santarelli MF, Ramazzotti A, Meloni A, De Marchi D, Favilli B, Cracolici E, Midiri M, Spasiano A, et al. NMR Biomed 2009 22 707 715 10.1002/nbm.1382 19322807
26. Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients. Meloni A, Positano V, Pepe A, Rossi G, DellAmico M, Salvatori C, Keilberg P, Filosa A, Sallustio G, Midiri M, et al. Magn Reson Med 2010 64 211 219 10.1002/mrm.22410 20572148
27. Deferasirox, Deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, et al. Haematologica 2011 96 41 47 10.3324/haematol.2009.019042 20884710
28. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. Link G, Saada A, Pinson A, Konijn AM, Hershko C, J Lab Clin Med 1998 131 466 474 10.1016/S0022-2143(98)90148-2 9605112 (Pubitemid 28259763)
29. Mitochondrial dysfunction in cardiac disease: ischemia-reperfusion, aging, and heart failure. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL, J Mol Cell Cardiol 2001 33 1065 1089 10.1006/jmcc.2001.1378 11444914 (Pubitemid 32579276)
30. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, Munnich A, Cabantchik ZI, Blood 2008 112 5219 5227 10.1182/blood-2008-06-161919 18796625
31. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study. Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L, Eur J Haematol 2010 85 36 42 20331740